Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

DSpace Repository

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

Author: Long, G. V.; Flaherty, K. T.; Stroyakovskiy, D.; Gogas, H.; Levchenko, E.; de Braud, F.; Larkin, J.; Garbe, C.; Jouary, T.; Hauschild, A.; Chiarion-Sileni, V.; Lebbe, C.; Mandala, M.; Millward, M.; Arance, A.; Bondarenko, I.; Haanen, J. B. A. G.; Hansson, J.; Utikal, J.; Ferraresi, V.; Mohr, P.; Probachai, V.; Schadendorf, D.; Nathan, P.; Robert, C.; Ribas, A.; Davies, M. A.; Lane, S. R.; Legos, J. J.; Mookerjee, B.; Grob, J. -J.
Tübinger Autor(en):
Garbe, Claus
Published in: Annals of Oncology (2017), Bd. 28, H. 7, S. 1631-1639
Verlagsangabe: Oxford Univ Press
Language: English
Full text: http://dx.doi.org/10.1093/annonc/mdx176
ISSN: 1569-8041
DDC Classifikation: 610 - Medicine and health
Dokumentart: Artikel
Show full item record

This item appears in the following Collection(s)